- A Phase 2 clinical trial, LOGRA, assessing vTv Therapeutics' (NASDAQ:VTVT) TTP273 for glycemic control in type 2 diabetics, is underway. The primary endpoint of the 156-subject study is the change in HbA1c from baseline at Week 12. According to clinicaltrials.gov, the estimated final data collection date for the primary endpoint is October 2016. The estimated study completion date is November 2016.
-
TTP273, utilizing the company's TTP Translational Technology, is an orally administered glucagon-like peptide-1 receptor (GLP-1R) agonist. Its value proposition is the avoidance of injections and gastrointestinal side effects like nausea and vomiting.
- Type 2 diabetes (T2D), representing up to 95% of diabetes cases, develops over time in response to age, diet, weight and (lack of) exercise. The goal, difficult to achieve, is to maintain an HbA1c level below 7%.
-
Update: On August 16, the company announced that enrollment was completed.